Short Interest Reporting: Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Has Increase in Shorts

November 23, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Reporting: Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Has Increase in Shorts

The stock of Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) registered an increase of 1.33% in short interest. ADMS’s total short interest was 3.82M shares in November as published by FINRA. Its up 1.33% from 3.77 million shares, reported previously. With 122,700 shares average volume, it will take short sellers 31 days to cover their ADMS’s short positions. The short interest to Adamas Pharmaceuticals Incorporated’s float is 27.89%. About 35,271 shares traded hands. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 15.43% since April 21, 2016 and is downtrending. It has underperformed by 20.76% the S&P500.

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $328.78 million. The Firm is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems . It currently has negative earnings. The Company’s segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Out of 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 86% are positive. Adamas Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Cowen & Co initiated the shares of ADMS in a report on Tuesday, January 19 with “Outperform” rating. The firm has “Sell” rating given on Friday, October 16 by TheStreet. Aegis Capital initiated Adamas Pharmaceuticals Inc (NASDAQ:ADMS) on Tuesday, September 22 with “Buy” rating. Mizuho maintained the stock with “Neutral” rating in Thursday, April 28 report. JMP Securities initiated the stock with “Market Outperform” rating in Friday, April 1 report. Mizuho initiated the stock with “Neutral” rating in Tuesday, January 19 report. The firm earned “Buy” rating on Thursday, June 16 by Mizuho. Zacks downgraded the shares of ADMS in a report on Friday, August 7 to “Buy” rating. The rating was maintained by Credit Suisse with “Outperform” on Thursday, December 24. Mizuho maintained the shares of ADMS in a report on Thursday, September 8 with “Buy” rating.

ADMS Company Profile

Adamas Pharmaceuticals, Inc., incorporated on November 15, 2000, is a pharmaceutical company. The Firm is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). The Firm is engaged in modifying the pharmacokinetic profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. The Company’s segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The Firm has selected aminoadamantanes as its initial area of focus, which have the ability to modulate multiple neurotransmitter systems, which are the molecular pathways that control brain function.

More important recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on June 21, 2011, also Fool.com published article titled: “Why Adamas Pharmaceuticals Dropped 25.3% in February”, Fool.com published: “Here’s Why Adamas Pharmaceuticals’ Stock Soared Today” on December 23, 2015. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was released by: Seekingalpha.com and their article: “Invest In Adamas Pharmaceuticals For Its Parkinson’s Disease Candidate” with publication date: July 05, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>